TaiGen Biotechnology Deal History & Licensing Activity
TaiGen Biotechnology is a life sciences. Over the past three years, TaiGen Biotechnology has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 1 active clinical trial, primarily in Hematology.
Deals (12mo)
1
Active Trials
1
Top Modality
Small Molecules
Focus Area
Hematology
TaiGen Biotechnology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving TaiGen Biotechnology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ISM4808 | Insilico Medicine | Small Molecules | Phase 1 | license | Mar 2026 |
TaiGen Biotechnology Pipeline Focus
Therapeutic areas and modalities where TaiGen Biotechnology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
TaiGen Biotechnology Strategic Signals
Key indicators of TaiGen Biotechnology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
TaiGen Biotechnology Clinical Pipeline
TaiGen Biotechnology has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches TaiGen Biotechnology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About TaiGen Biotechnology Licensing & Deal Activity
TaiGen Biotechnology is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, TaiGen Biotechnology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for TaiGen Biotechnology include Hematology (2 deals and trials). In terms of modality, TaiGen Biotechnology has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for TaiGen Biotechnology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against TaiGen Biotechnology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.